Eleven studies comprising a total of 1244 patients reported the POAF in
patients pretreated with atorvastatin or
placebo25-29,32-37 . Atorvastatin was
correlated to a reduced prevalence of POAF (133/627 [21.2%] versus
201/617 [32.6%]). There was a statistically significant difference
between the considered groups (OR 0.54; 95% CI: 0.41 to 0.70, p-value
< 0,00001). There was severe heterogeneity observed between
the 11 studies (I2= 65%) (Figure 9 ).
However, If we only consider studies with ≥ 199 patients, the results
are different (OR 0.74; 95% CI: 0.54 to 1.03, p-value = 0.08;
I2=
83%) (Figure 10 ).